Cytotoxic effect of the immunotoxin constructed of the ribosome-inactivating protein curcin and the monoclonal antibody against Her2 receptor on tumor cells

Bioscience, Biotechnology and Biochemistry

Volumn 79, Issue 6, 2015, Pages 896-906

  Jaramillo Quintero, Lidia Patricia ^a   De Oca, Arturo Contis Montes ^a   Rojas, Andrés Romero ^b   Rojas Hernández, Saúl ^a   Campos Rodríguez, Rafael ^a   Martínez Ayala, Alma Leticia ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Breast cancer; Chemical conjugation; ErBB2; Reductive amination; Targeted therapy

Indexed keywords

AMINES; CELL CULTURE; CELLS; CYTOTOXICITY; DISEASES; ELECTROPHORESIS; MONOCLONAL ANTIBODIES; PROTEINS;

BREAST CANCER; BREAST CANCER CELLS; ERBB2; IMMUNOCYTOCHEMISTRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; REDUCTIVE AMINATION; RIBOSOME-INACTIVATING PROTEIN; TARGETED THERAPY;

ANTIBODIES;

CURCIN PROTEIN, JATROPHA CURCAS; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; IMMUNOTOXIN; MONOCLONAL ANTIBODY; RIBOSOME INACTIVATING PROTEIN 1;

AMINATION; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; HUMAN; IMMUNOLOGY; METABOLISM; OXIDATION REDUCTION REACTION; PHYSICAL CHEMISTRY; PROTEIN CONFORMATION; TUMOR CELL LINE;

AMINATION; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COMPUTER SIMULATION; HUMANS; IMMUNOTOXINS; MODELS, MOLECULAR; OXIDATION-REDUCTION; PHYSICOCHEMICAL PROCESSES; PROTEIN CONFORMATION; RECEPTOR, ERBB-2; RIBOSOME INACTIVATING PROTEINS, TYPE 1;

EID: 84940038124     PISSN: 09168451     EISSN: 13476947     Source Type: Journal    
DOI: 10.1080/09168451.2015.1006572     Document Type: Article

References (41)

1. Tan M, Yu D. Molecular mechanisms of ErbB2-mediated breast cancer chemoresistance. In: Dihua Y, Mien-Chie H, editors. Breast cancer chemosensitivity. New York, (NY): Landes Bioscience/Springer Science+Business Media LLC; 2007. p. 119-129.
2. Kumar PS, Pegram M. HER2 targeted therapy in breast cancer... beyond Herceptin. Rev. Endocr. Metab. Disord. 2007; 8:269-277.
3. Ávila DA, Calderón FC, Pérez MR, Pons C, Pereda MC, Ortiz RA. Construction of an immunotoxin by linking a monoclonal antibody against the human epidermal growth factor receptor and a hemolytic toxin. Biol. Res. 2007; 40:173-183.
4. Choudhary S, Mathew M, Verma RS. Therapeutic potential of anticancer immunotoxins. Drug Discovery Today. 2011; 16: 495-503.
5. Madhumathi J, Verma RS. Therapeutic targets and recent advances in protein immunotoxins. Curr. Opin. Microbiol. 2012; 15:300-309.
6. Fracasso G, Stirpe F, Colombatti M. Ribosome-inactivating protein containing conjugates for therapeutic use. In: Lord JM, Hartley MR, editors. Toxic plant proteins 18, plant cell monographs. Berlin: Springer-Verlag: Germany; 2010. p. 225-263.
7. Endo Y, Wool GI. The site of action of α-sarcin on eukaryotic ribosomes. The sequence at the α-sarcin cleavage site in 28s ribosomal ribonucleic acid. J Biol Chem. 1982; 257:9054-9060.
8. Lin J, Chen Y, Xu Y., Yan F, Tang L, Chen F. Cloning and expression of curcin, a ribosome-inactivating protein from the seeds of Jatropha curcas. Acta Bot. Sin. 2003; 45:858-863.
9. Ikawati Z, Sudjadi, Sismindari. Cytotoxicity against tumor cell lines of a ribosome-inactivating protein (rip)-like protein isolated from leaves of Mirabilis jalapa. L. Malays. J. Pharm. Sci. 2006; 4:31-41.
10. De Virgilio M, Lombardi A, Caliandro R., Fabbrini MS. Ribosome-inactivating proteins: From plant defense to tumor attack. Toxins. 2010; 2:2699-2737.
11. Puri M, Kaur I, Perugini M.A., Gupta RC. Ribosome-inactivating proteins: Current status and biomedical applications. Drug Discovery Today. 2012; 17:774-783.
12. Dosio F, Brusa P, Cattel L. Immunotoxins and anticancer drug conjugate assemblies: The role of the linkage between components. Toxins. 2011; 3:848-883.
13. Antignani A, FitzGerald D. Immunotoxins: The Role of the Toxin. Toxins. 2013; 5:1486-1502.
14. Pastan I, Hassan R, FitzGerald D.J., Kreitman RJ. Immunotoxin treatment of cancer. Annu. Rev. Med. 2007; 58:221-237.
15. Teicher BA, Chari RVJ. Antibody conjugate therapeutics: Challenges and potential. Clin. Cancer Res. 2011; 17:6389-6397.
16. Farkaš P, Bystrický S. Chemical conjugation of biomacromole-cules: A mini-review. Chem. Pap. 2010; 64:683-695.
17. Li Z, Trick HN. Rapid method for high-quality RNA isolation from seed endosperm containing high levels of starch. BioTechniques. 2005; 38:872-876.
18. Endo Y, Tsurugi K. The RNA N-glycosidase activity of ricin A-chain. J. Biol Chem. 1988; 263:8735-8739.
19. Tumer NE, Hwang D, Bonnes M. C-terminal deletion mutant of pokeweed antiviral protein inhibits viral infection but does not depurinate host ribosomes. Proc. Nat. Acad. Sci. USA. 1997; 94:3866-3871.
20. Dubois M, Gilles KA, Hamilton J.K., Rebers PA, Smith F. Colorimetric method for determination of sugars and related substances. Anal. Chem. 1956; 28:350-356.
21. Bradford MM. Rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976; 72:248-254.
22. I-TASSER. Available from: http://zhanglab.ccmb.med.umich.edu/I-TASSER/.
23. PROCHECK. Available from: http://www.ebi.ac.uk/thornton-srv/software/PROCHECK/.
24. Daubenfeld T, Hossan M, Trommer W.E., Niedner-Schatteburg G. On the contentious sequence and glycosylation motif of the ribosome inactivating plant protein gelonin. Biochem. Biophys. Res. Commun. 2005; 333:984-989.
25. SWEET-II. Available from: http://www.glycosciences.de/modeling/sweet2/.
26. GlyProt. Available from: http://www.glycosciences.de/modeling/glyprot/php/main.php.
27. MOE. Available from: http://www.chemcomp.com/MOE-Molecular-Modeling-and-Simulations.
28. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bateriophage. Nature. 1970; 227:680-685.
29. Stirpe F. Ribosome-inactivating proteins. Toxicon. 2004; 44: 371-383.
30. Lin J, Zhou X, Wang J., Jiang P, Tang K. Purification and characterization of curcin, a toxic lectin from the seed of jatropha curcas. Prep. Biochem Biotechnol. 2010; 140:107-118.
31. NCBI. Available from: http://www.ncbi.nlm.nih.gob.
32. Zhang Y, Skolnick J. Automated structure prediction of weakly homologous proteins on a genomic scale. Proc. Nat. Acad. Sci. USA. 2004; 101:7594-7599.
33. Luo M, Yang X, Liu W., Xu Y, Huang P, Yan F., Chen F. Expression, purification and anti-tumor activity of curcin. Acta Biochim. Biophys. Sin. 2006; 38:663-668.
34. Zhao Q, Wang W, Wang Y., Xu Y, Chen F. The effect of curcin from Jatropha curcas on apoptosis of mouse sarcoma-180 cells. Fitoterapia. 2012; 83:849-852.
35. DanDan X, Bo Z, YaDong H., QiHao Z, ZhiJian S, Hua X., Qing Z. Expression of recombinant curcin in Jatropha curcas L. and its anti-tumor activity in vitro. Med. Plant. 2012; 3:68-71.
36. Mohamed SM, Veeranarayanan S, Minegishi H., Sakamoto Y, Shimane Y, Nagaoka Y., Aki A, Poulose CA, Echigo A, Yoshida Y, Maekawa T, Kumar DS. Cytological and subcellular response of cells exposed to the type-1 RIP curcin and its hemocompati-bility analysis. Sci. Rep. 2014; 4:5747.
37. Zheng Q, Xiong Y-L, Su Z-J, Zhang Q-H, Dai X-Y, Li L-Y, Xiao X, Huang Y-D. Expression of curcin-transferrin receptor binding peptide fusion protein and its anti-tumor activity. Protein Express Purif. 2013; 89:181-188.
38. Mohamed SM, Veeranarayanan S, Poulose A.C., Nagaoka Y., Minegishi H, Yoshida Y, Maekawa T., Kumar DS. Type 1 ribo-toxin-curcin conjugated biogenic gold nanoparticles for a multimodal therapeutic approach towards brain cancer. Biochimic. et Biophys. Acta. 2014; 1840:1657-1669.
39. Gildersleeve CJ, Oyelaran O, Simpson T.J., Allred B. Improved procedure for direct coupling of carbohydrates to proteins via reductive amination. Bioconjugate Chem. 2008; 19:1485-1490.
40. Hermanson TG. Bioconjugate techniques. 3rd ed. New York (NY): Academic Press; 2013.
41. Kumar KR, Xiavour S, Latha S., Kumar V. Sukumaran. Antihuman IgG-horseradish peroxidase conjugate preparation and its use in ELISA and Western Blotting experiments. J. Chromatogr. Sep. Tech. 2014; 5:211. doi:10.4172/2157-7064.1000211.